Web Desc
Hepatobiliary Cancers: Pathobiology and Translational Advances - VIRTUAL CONTENT AVAILABLE ON DEMAND
joint with Fatty Liver Disease and Multi-System Complications - VIRTUAL CONTENT AVAILABLE ON DEMAND
Organizer(s): Alphonse E. Sirica, Gregory J. Gores and Lopa Mishra
Date: March 22 - 24, 2021
Location: Virtual at your computer. Recorded presentation content is available On Demand.
Supported by the Directors' Fund
For important information on the coronavirus, please click here
Summary of Meeting:
Hepatobiliary cancers, including hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinomas (iCCA), represent a major global health burden, with hepatobiliary cancers being the second or third leading cause of cancer mortality worldwide. Moreover, with the rising trends in emerging cases, this field continues to challenge biological researchers and clinicians. This Keystone Symposia conference will be the first of its kind to focus specifically on this challenging disease. The conference aims to integrate emerging basic and translational research with the clinical perspective, in order to advance our understanding of the pathobiology behind both HCC and iCCA, with the ultimate goal of guiding novel treatment and prevention strategies targeting these underlying mechanisms. The program will explore current challenges in the field, including (1) shifting etiological trends, focusing on mechanisms linked to cell injury, inflammation, and fibrogenesis; (2) roles of the microbiome and tumor microenvironment in affecting disease progression, therapeutic resistance, and immunosurveillance; (3) challenges of inter- and intra-tumoral heterogeneity; (4) identification of novel and more effective biomarker signatures for monitoring prognosis and treatments; (5) advances in “omics” for personalizing therapies; and (6) current and emerging trends in molecular and immune targeting. Moreover, this unique conference is being paired with a joint meeting entitled Fatty Liver Disease and Multi-System Complications, which is highly complementary in view of the fact that non-alcoholic steatohepatitis is an important risk factor for hepatobiliary cancer. These joint meetings will foster new and productive research collaborations towards both basic and translational advances, as well as offer valuable training opportunities for basic researchers and physician scientists.
Scholarship Deadline: November 1 2020
Abstract Deadline: February 25 2021
We gratefully acknowledge additional support for this conference from:
Mayo Clinic Hepatobiliary SPORE
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Monday, March 22 | 8:00AM - 9:10AM
Welcoming Remarks and Keynote Session (Joint) (8am Denver/Mo
untain Time Start)

Speaker 1 of 4
* Jay D. Horton, University of Texas Southwestern Medical Center, USA

Monday, March 22 | 8:00AM - 9:10AM
Welcoming Remarks and Keynote Session (Joint) (8am Denver/Mo
untain Time Start)

Speaker 2 of 4
* Alphonse E. Sirica, Virginia Commonwealth University, USA

Monday, March 22 | 8:00AM - 9:10AM
Welcoming Remarks and Keynote Session (Joint) (8am Denver/Mo
untain Time Start)

Speaker 3 of 4
Helen H. Hobbs, University of Texas Southwestern Medical Center, USA
[NOT AVAILABLE ON DEMAND] PNPLA3's Role in NAFLD

Monday, March 22 | 8:00AM - 9:10AM
Welcoming Remarks and Keynote Session (Joint) (8am Denver/Mo
untain Time Start)

Speaker 4 of 4
Hashem B. El-Serag, Baylor College of Medicine, USA
Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers

Monday, March 22 | 9:10AM - 11:00AM
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fi
brogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint) (9:10am Denver/Mountain Time Start)


Speaker 1 of 7
* Jay D. Horton, University of Texas Southwestern Medical Center, USA

Monday, March 22 | 9:10AM - 11:00AM
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fi
brogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint) (9:10am Denver/Mountain Time Start)


Speaker 2 of 7
* Alphonse E. Sirica, Virginia Commonwealth University, USA

Monday, March 22 | 9:10AM - 11:00AM
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fi
brogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint) (9:10am Denver/Mountain Time Start)


Speaker 3 of 7
Lopa Mishra, George Washington University, USA
A TGF-ß-ALDH2 Axis in Obesity, Metabolic Syndrome, and HCC

Monday, March 22 | 9:10AM - 11:00AM
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fi
brogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint) (9:10am Denver/Mountain Time Start)



Coffee Break

Monday, March 22 | 9:10AM - 11:00AM
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fi
brogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint) (9:10am Denver/Mountain Time Start)


Speaker 5 of 7
Maria Rescigno, Humanitas University, Italy
The Gut-Liver Axis in Liver Cancer Risk Conditions

Monday, March 22 | 9:10AM - 11:00AM
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fi
brogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint) (9:10am Denver/Mountain Time Start)


Speaker 6 of 7
Daniel A. Heller, Memorial Sloan Kettering Cancer Center, USA
Lipid Dysregulation in Inflammation, NASH, and Cancer

Monday, March 22 | 9:10AM - 11:00AM
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fi
brogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint) (9:10am Denver/Mountain Time Start)


Speaker 7 of 7
Juan R. Sanabria, Marshall University/Case Western Reserve University, USA
Short Talk: The a1-Na/K-ATPase/Src-p/PI3K Pathway Modulates the Survivin-SMAC Apoptotic “Switch” in NASH Related Hepatocellular Carcinoma: A Translational Study

Monday, March 22 | 12:30PM - 1:30PM
Career Roundtable (Joint) (12:30pm Denver/Mountain Time Star
t)


Speaker 1 of 3
Kendra K. Bence, Pfizer Inc., USA

Monday, March 22 | 12:30PM - 1:30PM
Career Roundtable (Joint) (12:30pm Denver/Mountain Time Star
t)


Speaker 2 of 3
Augusto Villanueva Rodriguez, Icahn School of Medicine at Mount Sinai, USA

Monday, March 22 | 12:30PM - 1:30PM
Career Roundtable (Joint) (12:30pm Denver/Mountain Time Star
t)


Speaker 3 of 3
Xin Wei Wang, NCI, National Institutes of Health, USA

Monday, March 22 | 2:00PM - 3:00PM
Poster Session 1 (Joint) (2pm Denver/Mountain Time Start)


Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)


Speaker 1 of 10
* Lopa Mishra, George Washington University, USA

Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)


Speaker 2 of 10
Silvia Affo, Columbia University, USA
Role of Cancer Associated Fibroblasts in Cholangiocarcinoma

Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)


Speaker 3 of 10
Amaia Lujambio, Icahn School of Medicine at Mount Sinai, USA
Mechanisms of Immune Escape in Hepatocellular Carcinoma

Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)


Speaker 4 of 10
Alphonse E. Sirica, Virginia Commonwealth University, USA
The Desmoplastic Reaction and Intrahepatic Cholangiocarcinoma Progression: CAFs, Select Molecular Drivers, and Prognostic Implications

Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)



Coffee Break

Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)


Speaker 6 of 10
* Gregory J. Gores, Mayo Clinic, USA
Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy

Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)


Speaker 7 of 10
Yuhua Xue, University of Pittsburgh, USA
Short Talk: p-Ezrin (Thr567) Synergizes with Akt Signaling to Accelerate Yap Mediated Cholangiocarcinogenesis but Correlates with a Favorable Prognosis in Human Intrahepatic Cholangiocarcinoma(ICC) Patients

Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)


Speaker 8 of 10
Wen-Xing Ding, University of Kansas Medical Center, USA
Short Talk: SQSTM1/p62 Inhibits whereas Nrf2 Promotes Tumorigenesis by Inducing Cell Population Remodeling and Metabolic Reprograming in Mouse Livers with mTORC1 Activation and Defective Autophagy

Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)


Speaker 9 of 10
Haichuan Wang, University of California, San Francisco, USA
Short Talk: Requirement of Hippo Signaling Cascade during AXIN1 Mutation Driven Hepatocarcinogenesis

Monday, March 22 | 3:00PM - 6:10PM
Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver
/Mountain Time Start)


Speaker 10 of 10
Juan Pablo Unfried, University of Navarra, Spain
Short Talk: Long Non-Coding RNA NIHCOLE Promotes the DNA Damage Repair of Hepatocellular Carcinoma Cells

Monday, March 22 | 3:00PM - 5:10PM
Genetics of NAFLD (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 1 of 9
* Jay D. Horton, University of Texas Southwestern Medical Center, USA


Monday, March 22 | 3:00PM - 5:10PM
Genetics of NAFLD (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 2 of 9
* Henry N. Ginsberg, Columbia University Vagelos College of Physicians and Surgeons, USA


Monday, March 22 | 3:00PM - 5:10PM
Genetics of NAFLD (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 3 of 9
Elizabeth K. Speliotes, University of Michigan, USA
Use of GWAS to Identify SNPs Associated with NAFLD


Monday, March 22 | 3:00PM - 5:10PM
Genetics of NAFLD (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 4 of 9
Noura S. Abul-Husn, Icahn School of Medicine at Mount Sinai, USA
Genomics and Liver Disease in Diverse Populations: From Biobanks to Patients


Monday, March 22 | 3:00PM - 5:10PM
Genetics of NAFLD (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 5 of 9
Karthickeyan Chella Krishnan, University of Cincinnati, USA
Short Talk: Mouse and Human Population Studies Revealed Sex-Specific Roles of Liver Pyruvate Kinase in Promoting NAFLD/NASH


Monday, March 22 | 3:00PM - 5:10PM
Genetics of NAFLD (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 6 of 9
Mohammad Kabbani, Rockefeller University, USA
Short Talk: Human Hepatocyte PNPLA3 148M Exacerbates Rapid Non-Alcoholic Fatty Liver Disease Development in Chimeric Mice


Monday, March 22 | 3:00PM - 5:10PM
Genetics of NAFLD (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease


Coffee Break


Monday, March 22 | 3:00PM - 5:10PM
Genetics of NAFLD (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 8 of 9
Ester Dohnalkova, Mayo Clinic, USA
Short Talk: Hepatocyte-Specific Deletion of ROCK1 Prevents Liver Inflammation and Fibrosis in Murine Nonalcoholic Steatohepatitis


Monday, March 22 | 3:00PM - 5:10PM
Genetics of NAFLD (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 9 of 9
Neil A. Youngson, Institute of Hepatology, UK
Short Talk: Acetyl-CoA Metabolism Drives Epigenome Change in Steatosis Leading to Widespread Abnormal Transcription and DNA Damage


Monday, March 22 | 5:10PM - 6:00PM
NAFLD and CVD (5:10pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 1 of 2
* Henry N. Ginsberg, Columbia University Vagelos College of Physicians and Surgeons, USA
The AAA Atpase Torsin A, a New, Potent Player in VLDL Secretion, NAFL, and NASH


Monday, March 22 | 5:10PM - 6:00PM
NAFLD and CVD (5:10pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 2 of 2
* Jay D. Horton, University of Texas Southwestern Medical Center, USA
Molecular Mediators of NAFLD and Hyperlipidemia


Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)


Speaker 1 of 10
* Gregory J. Gores, Mayo Clinic, USA

Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)


Speaker 2 of 10
* Alphonse E. Sirica, Virginia Commonwealth University, USA

Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)


Speaker 3 of 10
Yujin Hoshida, UT Southwestern Medical Center, USA
Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts

Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)


Speaker 4 of 10
Augusto Villanueva Rodriguez, Icahn School of Medicine at Mount Sinai, USA
Liquid Biopsy in Hepatobiliary Cancers

Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)


Speaker 5 of 10
Jessica Zucman-Rossi, University Paris Descartes-HEGP, France
Mechanisms of Liver Carcinogenesis Define Specific Molecular and Phenotypic HCC Subgroups

Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)



Coffee Break

Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)


Speaker 7 of 10
Jesper Bøje Andersen, University of Copenhagen, Denmark
Defining Distinct Subtypes of Intrahepatic Cholangiocarcinoma by Molecular Profiling: Diagnostic, Prognostic, and Therapeutic Applications

Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)


Speaker 8 of 10
Robert F. Schwabe, Columbia University, USA
Discovery of Subgroup-Specific HCC Master Regulators by Systems Biology Approaches

Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)


Speaker 9 of 10
Kerstin Seidel, Genentech, USA
Short Talk: Notch Inhibition Regresses Progenitor-Like HCCs by Inducing Hepatocyte Differentiation through Controlling C/EBPa Expression and HNF4a Activity

Tuesday, March 23 | 8:00AM - 11:10AM
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am
Denver/Mountain Time Start)


Speaker 10 of 10
Sungjin Ko, University of Pittsburgh, USA
Short Talk: NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming into Intrahepatic Cholangiocarcinoma

Tuesday, March 23 | 8:00AM - 11:00AM
Role of Lipids in NAFLD (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 1 of 9
Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA
Circadian Contributions to NAFLD


Tuesday, March 23 | 8:00AM - 11:00AM
Role of Lipids in NAFLD (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 2 of 9
* Catherine Postic, INSERM Institut Cochin, France
Altered Insulin Signaling and Glucose Toxicity in NAFLD


Tuesday, March 23 | 8:00AM - 11:00AM
Role of Lipids in NAFLD (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 3 of 9
* Hannele Yki-Järvinen, University of Helsinki, Finland
Effects of Genetic Risk Factors for NAFLD on Hepatic Lipid Metabolism


Tuesday, March 23 | 8:00AM - 11:00AM
Role of Lipids in NAFLD (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease


Coffee Break


Tuesday, March 23 | 8:00AM - 11:00AM
Role of Lipids in NAFLD (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 5 of 9
Eran Elinav, Weizmann Institute of Science, Israel
Host Microbiome Interactions in Health and Disease


Tuesday, March 23 | 8:00AM - 11:00AM
Role of Lipids in NAFLD (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 6 of 9
HongMin Ni, University of Kansas Medical Center, USA
Short Talk: Lack of VMP1 Impairs Hepatic Lipoprotein Secretion and Promotes Nonalcoholic Steatohepatitis in Mice


Tuesday, March 23 | 8:00AM - 11:00AM
Role of Lipids in NAFLD (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 7 of 9
Joanne Hsieh, Columbia University, USA
Short Talk: Sexually Dimorphic Mechanisms of Action of TTC39B in Hepatic Lipogenic Gene Expression


Tuesday, March 23 | 8:00AM - 11:00AM
Role of Lipids in NAFLD (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 8 of 9
Xiao-Wei Chen, Peking University, China
Short Talk: An ER Lipid Scramblase (ELS) Safeguards Lipoprotein Biogenesis and Lipid Homeostasis


Tuesday, March 23 | 8:00AM - 11:00AM
Role of Lipids in NAFLD (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 9 of 9
Zhaoyue Zhang, Princeton University, USA
Short Talk: Serine Catabolism Generates NADPH to Support Hepatic Lipogenesis


Tuesday, March 23 | 12:30PM - 1:30PM
Meet the Editors (Joint) (12:30pm Denver/Mountain Time Start
)

Speaker 1 of 3
Elena Bellafante, Med - Cell Press, UK

Tuesday, March 23 | 12:30PM - 1:30PM
Meet the Editors (Joint) (12:30pm Denver/Mountain Time Start
)

Speaker 2 of 3
Francesco Giovinazzo, Frontiers Journals, Italy

Tuesday, March 23 | 12:30PM - 1:30PM
Meet the Editors (Joint) (12:30pm Denver/Mountain Time Start
)

Speaker 3 of 3
Xin (Cindy) Sun, Journal of Experimental Medicine at Rockefeller University Press, USA

Tuesday, March 23 | 2:00PM - 3:00PM
Poster Session 2 (Joint) (2pm Denver/Mountain Time Start)


Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)


Speaker 1 of 10
* Lopa Mishra, George Washington University, USA

Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)


Speaker 2 of 10
* Alphonse E. Sirica, Virginia Commonwealth University, USA

Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)


Speaker 3 of 10
Irene Oi Lin Ng, University of Hong Kong, Hong Kong
Molecular Biomarkers in Hepatocellular Carcinoma

Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)


Speaker 4 of 10
Xin Wei Wang, NCI, National Institutes of Health, USA
Causes and Functional Intricacies of Intertumor and Intratumor Heterogeneity in Primary Hepatobiliary Cancers

Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)


Speaker 5 of 10
Renumathy Dhanasekaran, Stanford University, USA
Implications of Genetic Heterogeneity in Hepatocellular Carcinoma (HCC)

Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)



Coffee Break

Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)


Speaker 7 of 10
Teh Bin Tean, Duke-NUS Medical School, Singapore
Genomic and Epigenomic Studies of Cholangiocarcinoma and their Clinical Implications

Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)


Speaker 8 of 10
Josep Llovet, Icahn School of Medicine at Mount Sinai, USA
Immune Therapies for HCC: is NASH-HCC Responding Different

Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)


Speaker 9 of 10
Bangyan Stiles, University of Southern California, USA
Short Talk: Heterogeneous Liver Cancer Development Promoted by PTEN Regulated beta-Catenin and SOX9 Signal

Tuesday, March 23 | 3:00PM - 6:10PM
Genomics, Molecular Heterogeneity, and Precision Medicine in
Hepatobiliary Cancers (3pm Denver/Mountain Time Start)


Speaker 10 of 10
Chungui Xu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospi, China
Short Talk: Gender Distinct in Genomic Features of HBV-Related Hepatocellular Carcinoma

Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 1 of 10
* Morris J. Birnbaum, Pfizer Inc., USA


Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 2 of 10
Mark A. McNiven, Mayo Clinic, USA
Lipid Droplet Formation and Lipophagy in Fatty Liver Disease


Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 3 of 10
* Tobias Walther, Harvard/HHMI, USA
Lipid Droplet Biology in NAFLD


Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 4 of 10
Annelise Poss, University of Utah, USA
Short Talk: Ceramides as Mediators of Endoplasmic Reticulum Stress in NASH


Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease


Coffee Break


Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 6 of 10
Cholsoon Jang, University of California, Irvine, USA
Short Talk: The Small Intestine Shields the Liver from Fructose-Induced Steatosis


Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 7 of 10
Kahealani Uehara, University of Pennsylvania, USA
Short Talk: Activation of Hepatic mTORC1 Protects Against NASH via Dual Regulation of VLDL- TAG Secretion and De Novo Lipogenesis


Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 8 of 10
Sabine Daemen, Washington University in St. Louis, USA
Short Talk: The Hepatic Crown-like Structure in NASH: A Nexus between Monocyte-Derived Macrophages, Hepatic Stellate Cells, and Tissue Fibrosis


Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 9 of 10
Samar Ibrahim, Mayo Clinic, USA
Short Talk: Lipid-Induced Endothelial Vascular Cell Adhesion Molecule 1 Promotes Nonalcoholic Steatohepatitis Pathogenesis


Tuesday, March 23 | 3:00PM - 5:20PM
Pathways to NASH (3pm Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 10 of 10
Wenke Jonas, German Institute of Human Nutrition, Germany
Short Talk: Immunity-Related GTPase IFGGA2 Induces Degradation of Hepatic Lipids by Lipophagy


Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 1 of 11
* Gregory J. Gores, Mayo Clinic, USA

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 2 of 11
* Lopa Mishra, George Washington University, USA

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 3 of 11
Tim F. Greten, NCI, National Institutes of Health, USA
Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 4 of 11
R. Kate Kelley, University of California, San Francisco, USA
Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 5 of 11
Bruno Sangro, Clinica Universidad de Navarra, Spain
Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)



Coffee Break

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 7 of 11
Miryam Müller, CRUK Beatson Institute, UK
Short Talk: Identifying Effective Subtype-Specific Treatment Responses in Hepatocellular Carcinoma in Genetically Engineered Mouse Models

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 8 of 11
Jonathan M. Hernandez, NCI, National Institutes of Health, USA
Short Talk: A Cytosolic Complex Between the Nuclear Export Protein XPO7 and Sterile 20-like Kinase (SLK) Drives Cholangiocarcinoma, and Reveals a Translatable Therapeutic Target

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 9 of 11
Massimiliano Cadamuro, University of Padua, Italy
Short Talk: Inhibition of YAP Activation Induces Cell Senescence and Autophagy while Blocking Cell Proliferation in Cholangiocarcinoma (CCA)

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 10 of 11
Man Hsin Cindy Hung, NCI, National Institutes of Health, USA
Short Talk: Tumor Methionine Metabolism Drives T-Cell Exhaustion in Hepatocellular Carcinoma

Wednesday, March 24 | 8:00AM - 10:55AM
Advances in Molecular and Immune Targeting of Hepatobiliary
Cancers (8am Denver/Mountain Time Start)


Speaker 11 of 11
Andreas Prokesch, Medical University Graz, Austria
Short Talk: Overcoming HCC Drug Resistance byTargeting Metabolic Flexibility Conferred by p53

Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 1 of 11
* Hannele Yki-Järvinen, University of Helsinki, Finland


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 2 of 11
* Morris J. Birnbaum, Pfizer Inc., USA
DGAT2 Inhibition for NASH


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 3 of 11
Chuhan Chung, Gilead Sciences, USA
Combination Therapies for NASH Cirrhosis


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 4 of 11
Greg Steinberg, McMaster University, Canada
Role of ATP Citrate Lyase (ACLY) in NASH and HCC


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 5 of 11
Kendra K. Bence, Pfizer Inc., USA
Inhibition of Fructose Metabolism for the Treatment of NAFLD


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease


Coffee Break


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 7 of 11
Lei Ling, NGM Biopharmaceuticals, USA
Therapeutic FGF19 in Non-Alcoholic Steatohepatitis


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 8 of 11
Aimee L. Edinger, University of California, Irvine, USA
Short Talk: A Drug-Like Sphingolipid Opposes Mitochondrial Fragmentation and Corrects the Metabolic Sequelae of Obesity


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 9 of 11
Brian Rady, Janssen R&D, USA
Short Talk: Inhibition of Hepatocyte Inflammasome Improves Features of NASH in foz/foz Mice


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 10 of 11
Haressh Sajiir, University of Queensland - Mater Research Institute, Australia
Short Talk: Development of Liver-Targeted Interleukin-22 for Fatty Liver Disease


Wednesday, March 24 | 8:00AM - 10:50AM
Emerging Therapies for NASH (8am Denver/Mountain Time Start)
This session is from Fatty Liver Disease

Speaker 11 of 11
Madhulika Tripathi, Duke-NUS Medical School Singapore, Singapore
Short Talk: HHcy is a Feature and Mediator of NASH that Permits B12 and Folate to be an Effective Therapy for NASH


Wednesday, March 24 | 10:50AM - 11:00AM
Closing Remarks (10:50am Denver/Mountain Time Start)
This session is from Fatty Liver Disease


Wednesday, March 24 | 10:55AM - 11:05AM
Closing Remarks (Organizers) (10:55am Denver/Mountain Time S
tart)



Wednesday, March 24 | 11:00AM - 12:00PM
Networking Lounge (Joint) (11am Denver/Mountain Time Start)


*Session Chair.